Field Medical Introduces Revolutionary Ablation System in Prague Trial

The FieldForce™ Ablation System, developed by Field Medical,™ Inc., introduces a cutting-edge contact force pulsed field ablation (PFA) technology designed to transform the management of life-threatening ventricular arrhythmias. This innovative system represents a significant advancement in cardiac care and is currently undergoing its first human trial at Na Homolce Hospital in Prague, Czech Republic.

The Ventricular Catheter Ablation Study (VCAS) is a pivotal investigation that aims to enroll up to 60 patients across five global sites to evaluate the safety and effectiveness of the FieldForce™ Ablation System. By addressing the limitations of existing PFA and RF ablation technologies, this system offers a more efficient and promising approach to treating ventricular arrhythmias.

Preliminary results from the VCAS study will be presented on May 16, 2024, at the Heart Rhythm Scientific Sessions in Boston, Massachusetts. This unveiling will provide crucial insights into how the FieldForce™ Ablation System could revolutionize the management of ventricular arrhythmias, potentially improving patient outcomes and quality of life.

The FieldForce™ Ablation System by Field Medical,™ Inc. represents a groundbreaking advancement in the field of cardiac ablation technology. With the ongoing VCAS study shedding light on its safety and efficacy, this system holds great promise in enhancing the treatment of ventricular arrhythmias and offering new hope to patients worldwide.